1. Home
  2. ABUS

as 05-17-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Founded: N/A Country:
United States
United States
Employees: N/A City: WARMINSTER
Market Cap: 530.3M IPO Year: N/A
Target Price: $4.33 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.44 EPS Growth: N/A
52 Week Low/High: $1.69 - $3.29 Next Earning Date: 05-02-2024
Revenue: $12,986,000 Revenue Growth: -60.80%
Revenue Growth (this year): -56.35% Revenue Growth (next year): 29.02%

Share on Social Networks:

Stock Insider Trading Activity of Arbutus Biopharma Corporation (ABUS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Sims Karen ABUS Chief Medical Officer Feb 1 '24 Sell $2.31 4,358 $10,077.88 125,542 SEC Form 4
HASTINGS DAVID C ABUS Chief Financial Officer Feb 1 '24 Sell $2.31 9,593 $22,183.81 181,907 SEC Form 4
Sofia Michael J. ABUS Chief Scientific Officer Feb 1 '24 Sell $2.31 9,982 $23,083.38 1,485,121 SEC Form 4
McElhaugh Michael J. ABUS Interim President & CEO Feb 1 '24 Sell $2.31 10,164 $23,504.25 1,504,793 SEC Form 4